SCHEMBL24596349

SCHEMBL24596349

COc1ccccc1Nc1nc(C(F)(F)F)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK19 Q9BWU1 1/20 0.46
ALK Q9UM73 1/20 0.46
MAPT P10636 8/20 0.44
ALDH1A1 P00352 6/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
POLB P06746 1/20 0.43
JAK2 O60674 1/20 0.41
NTRK1 P04629 1/20 0.41
TYK2 P29597 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596182 0.82 CCR4 (0.40) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL24596212 0.81 ULK1 (0.44) GAAKMT2AMEN1L3MBTL1
SCHEMBL24596326 0.81 TYK2 (0.46) MAPTLMNATYK2EGFR
SCHEMBL24596297 0.80 EPHX2 (0.47) MAPTALDH1A1GAAKMT2AKDM4E
SCHEMBL24596390 0.80 LMNA (0.45) MAPTNPC1RAB9AKMT2AKDM4E
SCHEMBL24596284 0.79 IGF1R (0.54) CDK19ALKKMT2AKDM4EPTK2
SCHEMBL24596209 0.78 CCR4 (0.44) L3MBTL1LMNAPOLBJAK3EGFR
SCHEMBL24596302 0.76 MAT2A (0.39) KMT2AMEN1LMNATDP1
SCHEMBL24596243 0.76 LMNA (0.41) ALDH1A1GAASMN1; SMN2LMNA
SCHEMBL24596343 0.75 SYK (0.37) MAPTALDH1A1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A CDK19 2836/4885ALK 4774/4885MAPT 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.